Five Studies to be Highlighted During Panel Discussion

San Francisco, May 9, 2004-The American Urological Association will present a briefing to members of the media highlighting new research on prostate cancer treatments and outcomes during the 99th Annual Scientific Meeting on May 9, 2004 in San Francisco. The briefing will take place at 10:00 a.m. and will be moderated by J. Brantley Thrasher, M.D., chair of the AUA Public Media Committee. Featured research will include:

15-Year Post-Prostatectomy Cancer-Specific and PSA Progression Rates: Long-term disease control rates and predictors following radical prostatectomy are the focus of this study, which indicates that radical prostatectomy provides excellent long-term cancer control, In men who experienced a rise in prostate-specific antigen (PSA) following surgery the probability of death from cancer was 23 percent and 38 percent at 10 and 15 years.

Geographic Variation in Treatment Types in African-American and non-Hispanic Whites: Racial disparity in the treatment of early-stage prostate cancer could be the cause of geographic variations in treatment rates, according to this study using data extracted from the NCI Surveillance, Epidemiology, Epidemiology and End Results (SEER) public use files from 1995-1999. The authors suggest that culturally biased health behaviors, provider bias and differential access to care could be the cause for the disparities.

10-Year Outcome Estimates for Salvage Radiation Therapy Following Radical Prostatectomy: In men with PSA progression following radical prostatectomy, salvage radiation is a treatment option. This study showed that 25 percent of men with PSA progression following surgery had durable responses to radiation therapy

Comparison of Post-Treatment Progression Rates following Treatment for Screen-Detected Malignancies: Prostate-cancer screening can help diagnose tumors at an early, curable stage. However, treatment preference can be controversial. The authors examine progression rates following five separate treatment options: Radical prostatectomy, brachytherapy, external beam radiation, hormone therapy and watchful waiting.

European Randomized Study of Screening for Prostate Cancer (Rotterdam): Final Results: Prostate volume and previous negative biopsy could be significant predictors for biopsy outcome at a second screening for prostate cancer, according to this report from the European Randomized Study of Screening for Prostate Cancer (ERSPC, Rotterdam Section). Authors speculate that a combination of predictors should be the indication to biopsy on a subsequent screening, rather than a fixed PSA threshold.

"These articles cover controversial topics in prostate cancer, Dr. Thrasher said. "This briefing is a must-attend."

About the American Urological Association

Founded in 1902 and headquartered outside Baltimore, MD, the AUA is the preeminent professional organization for urologists. The AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for its members. The AUA also offers UrologyHealth.org, a patient education resource developed by member experts.

Contact
Wendy Waldsachs Isett, AUA,
410-689-3789 (office)
410-977-4770 (cell)
wisett @auanet.org

Christy Rippel
Imre Communications
410-821-8220
christyr@imrecommunications com

Please log-in or register in order to submit comments.

Powered by AkoComment!